Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

ProKidney’s Rilparencel shows promise for CKD patients, with Phase 2 data expected in 2025. Learn why PROK stock is a “Buy” ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

利厄替尼治疗EGFR T790M突变阳性NSCLC关键IIB期临床研究中，共计入组了 301 例经既往EGFR-TKI治疗后进展的EGFR T790M突变阳性或原发性EGFR T790M突变阳性局部 ...

今日，恒瑞医药宣布，公司收到国家药品监督管理局（以下简称 “国家药监局”）核准签发关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，将 ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung ...

Hope is not passive wishing but an active, dynamic process. According to Hope Theory, hope involves two components: agency and pathways. Agency is the belief in one’s capability to act ...

The company is currently developing HT-001 with intentions of submitting a new drug application via the 505(b)(2) regulatory pathway, according to the company website.